Tubacin prevents neuronal migration defects and epileptic activity caused by rat Srpx2 silencing in utero.


  • Salmi Manal
  • Bruneau Nadine
  • Cillario Jennifer
  • Lozovaya Natalia
  • Massacrier Annick
  • Buhler Emmanuelle
  • Cloarec Robin
  • Tsintsadze Timur
  • Watrin Françoise
  • Tsintsadze Vera
  • Zimmer Céline
  • Villard Claude
  • Lafitte Daniel
  • Cardoso Carlos
  • Bao Lan
  • Lesca Gaetan
  • Rudolf Gabrielle
  • Muscatelli Françoise
  • Pauly Vanessa
  • Khalilov Ilgam
  • Durbec Pascale
  • Ben-Ari Yehezkel
  • Burnashev Nail
  • Represa Alfonso
  • Szepetowski Pierre

document type



Altered development of the human cerebral cortex can cause severe malformations with often intractable focal epileptic seizures and may participate in common pathologies, notably epilepsy. This raises important conceptual and therapeutic issues. Two missense mutations in the sushi repeat-containing protein SRPX2 had been previously identified in epileptic disorders with or without structural developmental alteration of the speech cortex. In the present study, we aimed to decipher the precise developmental role of SRPX2, to have a better knowledge on the consequences of its mutations, and to start addressing therapeutic issues through the design of an appropriate animal model. Using an in utero Srpx2 silencing approach, we show that SRPX2 influences neuronal migration in the developing rat cerebral cortex. Wild-type, but not the mutant human SRPX2 proteins, rescued the neuronal migration phenotype caused by Srpx2 silencing in utero, and increased alpha-tubulin acetylation. Following in utero Srpx2 silencing, spontaneous epileptiform activity was recorded post-natally. The neuronal migration defects and the post-natal epileptic consequences were prevented early in embryos by maternal administration of tubulin deacetylase inhibitor tubacin. Hence epileptiform manifestations of developmental origin could be prevented in utero, using a transient and drug-based therapeutic protocol.

more information